Adiponectin and Circulating Macrophage Phenotypes in Non-alcoholic Fatty Liver Disease (NAFLD)

The Relationship of Adiponectin With Circulating Macrophage Phenotypes in Non-alcoholic Fatty Liver Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01472120

Enrollment

160

Registered

2011-11-16

Start date

2011-12-31

Completion date

2013-01-31

Last updated

2011-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic Fatty Liver Disease

Brief summary

Detailed description

In peripheral blood; monocytes and macrophages are found in two phenotype; proinflammatory M1 and anti-inflammatory M2 phenotypes. M2 form is converted (or polarized) to M1 phenotype in various metabolic disorders such as obesity and type 2 diabetes mellitus. In addition, these forms also are related to insulin resistance and inflammation in adipose tissue. Today, there is no study that investigate the role of adiponectin an anti-inflammatory adipokine, on macrophage polarization in non-alcoholic fatty liver disease.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

20 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Persistently (at least 6 months) elevated aminotransferases * Ultrasonographic presence of bright liver without any other liver or biliary tract disease * Liver histology compatible with a diagnosis of NASH or SS

Exclusion criteria

* A history of alcohol consumption \>40 g/wk, as assessed by a detailed interview extended to family members * Morbid obesity \[body mass index (BMI) ≥40 kg/m2\], hypertension * Positive blood markers of viral, autoimmune, or celiac disease * Abnormal copper metabolism or thyroid function tests * A diagnosis of T2DM and systemic arterial hypertension * Total cholesterol (TC) ≥250 mg/dL, triglycerides (TG) ≥400 mg/dL, exposure to occupational hepatotoxins or drugs known to affect glucose and lipid metabolism

Design outcomes

Primary

Measure	Time frame
For laboratory analyses, the collection of all blood samples from the study participants.	Collection of blood samples in one year and analyses of data in 3 months.

Countries

Turkey (Türkiye)

Outcome results